NCT06522672

Brief Summary

This clinical study aims to evaluate the effectiveness of My Happy Flo, a dietary supplement, in alleviating period symptoms and heavy menstrual flows. The study involves 40 participants, who will take the supplement daily for three menstrual cycles. Primary outcomes, such as the severity of heavy flows, prolonged periods, cramps, mood, energy levels, cycle regulation, and fatigue, will be measured using validated questionnaires completed after each menstrual cycle. Secondary outcomes, including Vitamin D and Iron levels, will be assessed through blood tests at the beginning and end of the study period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 31, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 17, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 26, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2024

Completed
Last Updated

November 20, 2024

Status Verified

November 1, 2024

Enrollment Period

3 months

First QC Date

July 17, 2024

Last Update Submit

November 18, 2024

Conditions

Keywords

Menstrual HealthPeriod Symptoms

Outcome Measures

Primary Outcomes (1)

  • Improvement in Period Symptoms

    Measurement of heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue using validated questionnaires.

    Baseline (Day 0), Cycle 1, Cycle 2, and Cycle 3 - each Cycle is 28 days

Secondary Outcomes (2)

  • Changes in Vitamin D Level

    Baseline and Cycle 3 - each Cycle is 28 days

  • Changes in Iron Level

    Baseline and Cycle 3 - each Cycle is 28 days

Study Arms (1)

My Happy Flo Supplement

EXPERIMENTAL

Participants will take two capsules of My Happy Flo daily, preferably in the morning with 8-10 oz of water and a meal, for three menstrual cycles.

Dietary Supplement: My Happy Flo

Interventions

My Happy FloDIETARY_SUPPLEMENT

The intervention aims to alleviate period symptoms including heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue. Blood tests for Vitamin D and Iron levels will be conducted at Baseline and after the third menstrual cycle. Participants will complete validated questionnaires assessing period symptoms after each menstrual cycle.

My Happy Flo Supplement

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female, aged 18 or over
  • Experiencing heavy period flows
  • Two or more self-reported symptoms (prolonged periods, cramps, poor mood, fatigue, irregular cycle)
  • Signs of potential anemia or iron deficiency
  • No known allergies to the product ingredients
  • Willing to comply with study requirements and limit caffeine intake
  • Generally healthy - do not live with any uncontrolled chronic disease

You may not qualify if:

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
  • A diagnosis of sports anemia within the previous 6 months
  • Anyone with known severe allergic reactions that require an Epi-Pen
  • Women who are pregnant, breastfeeding, or trying to conceive
  • Anyone unwilling to follow the study protocol
  • Anyone who has undergone any surgeries or invasive treatments (such as immunotherapy, chemotherapy, radiation, or biological cancer) in the last 30 days or has any planned for the next 12 weeks
  • Anyone with a history of substance abuse
  • Anyone currently participating or planning to participate in a research study
  • Anyone taking prescription anticonvulsants (anti-seizure medications)
  • Anyone taking prescription anticoagulant medications (blood thinners)
  • Anyone taking any hormone-modulating medications (e.g., hormonal birth control, hormone replacement therapy, testosterone, tamoxifen, thyroid medications, etc.)
  • History of hysterectomy, oophorectomy, or other surgery to the reproductive organs
  • History of gynecologic cancer, such as cervical, ovarian, uterine, vaginal, or vulvar cancer
  • Currently experiencing menopausal or perimenopausal symptoms
  • Changes or cessation of hormonal birth control in the last three months
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Citruslabs

Santa Monica, California, 90404, United States

Location

MeSH Terms

Conditions

DysmenorrheaFatigue

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsPelvic PainPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 17, 2024

First Posted

July 26, 2024

Study Start

May 31, 2024

Primary Completion

August 31, 2024

Study Completion

August 31, 2024

Last Updated

November 20, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations